Denis Filby
15 Jun 2017
Re: As usual !! Yep. Me too. In for a long time via shares in other companies. Likewise I am making a big profit on earlier investments but a small loss on recent ones. Eight pounds will do me, but even then I will still keep a foot in the door, just in case.
pauloverdi
15 Jun 2017
As usual !! As I've said before 'The mm's giveth and the mm's taketh away' !!No matter what good news takes us up they immediately take it down the next day !!Does my head in and have booked my appointment at the Hat Shop !! So we go up and then as Usaul we drip down !! Is this the most frautrauting share ever ??Me De Gasser et al have held for over 10 years !! Yes we bought in at 70p and no complaints there then !! But lately, yet again, the frausyration reappears and the mm's mark it down !!I really have to get out soon the suspense is killing me !!Ciao Paulo
d gaser
14 Jun 2017
TheraSphere carcinoma therapy BTG have released the results of a pilot study that is evaluating the effectiveness of our TheraSphere yttrium-90 transarterial radioembolization therapy,this is a digital patient-engagement platform to educate and engage plus measure health-related quality of life in a patient group, with primary hepatocellular carcinoma undergoing treatment with the company's TheraSphere yttrium-90 transarterial radioembolization therapy. The digital patient engagement platform is the IO Loop service powered by HealthLoop (HealthLoop Software CompanyBE HAPPYDave Full story follow link [link]
up protherics
04 Jun 2017
Re: Zytiga/BTG945 Heorot I remember btg in the tech boom days.. I wasn't invested in them then.I originally held proteous/protherics.. BTG took them over as what at the time I considered at a considerable discount..Protherics portfolio consisted of// Crofab/Digifab/Voraxaze/BSE test licensed to enfer scientific. They also held some exciting future products// Sepsis and hypertynsion vaccine.Both the sepsis and hypertynsion have fallen by the way side.. Who knows these may be resurrected in the future..Personally I will be holding for probably another three years unless a takeover comes in..Everything now seems very positive unless there is a hidden piece of negative news in the pipeline.. If Varithena takes off next year after the new codes are issued then who knows where the price will g
Heorot
04 Jun 2017
Re: Zytiga/BTG945 I certainly hope it exceeds £10. I have been in this for many years and have stuck with it in the hope that eventually I can recoup my original investments, My averaged price of my holding sits at £10.58. It has been under £1 at one time so it has recovered a lot since then. Hope is eternal .
up protherics
04 Jun 2017
Zytiga/BTG945 Excellent news re Zytiga and BTG945INMO Zytiga sales should almost double during the next few years and add an extra 100 million in revenue to BTG if not more.There is also a licensing agreement for BTG945 in the future.. Which could potentially add similar royalties if trials are successful.Maybe we could still hit the £10 mark over the next few years.. It probably explains why the institutions have not lost faith. Personally I did not see this coming, but there must have something in their annual report.
vaselino
03 Jun 2017
Re: BBC-Zytiga study [link] have missed the RNS as can't find it. If news broken after market shut on Friday it should hopefully lead to a positive impact on the share price. Not often one hears the word "transformational" in the pharma industry[link]
pollysmate
03 Jun 2017
BTG 945 Good article in couple of papers today breakthrough treatment for ovarian cancer drug known as BTG945. BTG quoted as saying lookingor partner as goes into trials
dave297
03 Jun 2017
BBC-Zytiga study Interesting article on BBC health about results of expanded study into use of Zytiga & suggesting substantial potential to expand use to a much wider group of prostrate sufferers .Goid news for sufferers & for BTG .
up protherics
27 May 2017
IC Article Good write up in the investors chronicle this week.All very positive. It looks like we are back on a growth path over the next few years. INMO they worth holding for a bit longer. Just so long as the institutions keep holding.
up protherics
23 May 2017
now i understand The stock is not going anywhere until the recent acquisitions and varithena for faty people takes off.Institions will hold then sell out . INMO the thing to look for is how long they have been holding the stock.( I say thing as that is all spivs are). As they will need to show at least a 5 per cent return year on year return.DYOROn the road U
d gaser
22 May 2017
OPTALYSE PE Study for Lower Dose EKOS® OPTALYSE PE Study Demonstrates Safety and Efficacy of Shorter, Lower Dose EKOS® Therapy For Pulmonary Embolism Bothell, WA, 22 May 2017: BTG plc (LSE: BTG), the global specialist healthcare company, today highlights the results of the OPTALYSE PE trial, presented at the American Thoracic Society International Conference in Washington, D.C. The results show that pulmonary embolism (PE) can be treated effectively with EKOS® over a much shorter period and at safer thrombolytic doses far below the current standard, which will allow for scheduling flexibility and efficiencies in clinician time and drug costs. OPTALYSE PE included 101 patients with acute proximal PE at 17 centers randomized to one of four cohorts. All patients received therapeutic anticoagulation along with EKOSⓇ Acoustic Pulse Thrombolysis™ Therapy. The first cohort received 4mg per catheter of a standard clot dissolving medication called tissue plasminogen activator (tPA) over 2 hours. The second cohort received 4mg per catheter tPA over 4 hours. The third cohort received 6mg per catheter tPA over 6 hours. The fourth cohort received 12mg per catheter tPA over 6 hours. All cohorts saw a significant reduction in the main indicator of right heart strain from PE (measured as right ventricular to left ventricular diameter ratio (RV/LV)) by approximately 23 to 26 percent. This is consistent with results achieved in previous EKOS® studies when treatment was applied for 12 to 24 hours. The OPTALYSE PE results also showed a very low bleeding rate of 3% compared to 10% in the previous SEATTLE II study where patients were treated with 24mg for 12 or 24 hours. "OPTALYSE PE sets a new standard for PE treatment," said study author Dr. Victor Tapson of the Pulmonary and Critical Care Division at Cedars-Sinai Medical Center in Los Angeles. "This trial builds on a growing body of clinical evidence, including the ULTIMA and SEATTLE II studies, showing a significant reduction in right-heart strain with shorter treatment durations and lower tPA doses. In addition to moving patients out of danger more quickly, hospitals can potentially save significant intensive care, drug and clinician time and cost due to increased safety and shorter treatment durations." The study's authors include Dr. Tapson; Dr. Gregory Piazza and Dr. Samuel Goldhaber of Brigham and Women's Hospital, in Boston; Keith Sterling of Inova Alexandria Hospital, Alexandria, Virginia, Dr. Kenneth Ouriel of Syntactx, New York; and Ping-Yu Liu of the Fred Hutchinson Cancer Center, Seattle. "EKOS® is the only device cleared for the treatment of pulmonary embolism and with the OPTALYSE results, BTG is once again demonstrating our commitment to advancing the treatment of PE," said EKOS Vice President and General Manager Matt Stupfel. "Now patients can be treated in half the time and half the dose or less, providing greater flexibility to clinicians, improved safety to patients, and potential cost savings to hospitals." About Pulmonary EmbolismPulmonary Embolism (PE) is a condition that occurs when a piece of a blood clot breaks off from a clot in the legs and travels through the vasculature -- getting trapped in the Pulmonary Arteries. When this happens the clot keeps blood from getting to some areas of the lungs to receive oxygen. This may lead to excessive strain the right side of the heart, ultimately leading to heart failure and/or cardiovascular collapse. PEs can be immediately fatal, but if diagnosed and appropriate therapy started, mortality can be reduced from approximately 30 percent to less than 10 percent. About the EkoSonic® Endovascular SystemThe EKOS® system uses ultrasonic waves in combination with clot-dissolving thrombolytic drugs to effectively dissolve clots and restore healthy heart function and blood flow. In clinical studies EKOS® therapy has been shown to speed time-to-clot dissolution, increase clot removal and enhance clinical improvement compared to
pauloverdi
22 May 2017
Share price So we go up and then as Usaul we drip down !! Is this the most frautrauting share ever ??Me De Gasser et al have held for over 10 years !! Yes we bought in at 70p and no complaints there then !! But lately, yet again, the frausyration reappears and the mm's mark it down !!I really have to get out soon the suspense is killing me !!Ciao Paulo
up protherics
19 May 2017
Heres Hoping Personally I am still hoping for this to be taken over in the short term.£8.50 would be niceLooking at the results we are not going to get any increase in profits due to Lamtrada and Zytiga coming off patent. Also crofab is now under threatI just hope that Varithena and Reneurix start to increase revenue during the next six months. Otherwise we will be looking at reduced profits this time next year.INMO this really isn't going to add any value in the short to medium term. Unless of course they start paying dividend
d gaser
19 May 2017
BTG collaboration with cloud based health co Found this article regarding BTG and a global specialist healthcare company called HealthLoop, the company is a cloud-based platform that automates follow-up patient care, they have today announced a new collaboration based on IO Loop. This is an exclusive service from BTG that gives access to a turn-key digital support platform powered by Healthloop. IO Loop enables patients and their physicians to stay connected, providing improved pre-procedural patient instructions and ongoing follow-up care outside of the acute care setting. This service also provides the care team with patient-reported outcomes that help physicians meet the new reporting requirements of Medicare Access and CHIP Authorisation Act (MACRAPatients are the most underleveraged resource in the achievement of better health outcomes. IO Loop empowers patients by connecting them with their physician via a digital support platform, and fully engages them in their treatment journey. Online engagement before, during and after treatment has the potential to reduce physician burden, delivering the right information at the right time. The IO Loop service helps patients prepare for their treatment, track and report any symptoms, review key treatment information at the appropriate time, and provides a personalised follow-up care plan with appropriate advice.For the full info go to [link]
